Recurrence morbidity of olfactory neuroblastoma
Katie Melder,Jess C. Mace,Garret Choby,Joao Paulo Almeida,Pierre‐Olivier Champagne,Erik Chan,Jeremy Ciporen,Mark B. Chaskes,Juan Fernandez‐Miranda,Nicholas K. Fung,Paul Gardner,Peter Hwang,Keven Seung Yong Ji,Aristotelis Kalyvas,Keonho A. Kong,Chirag Patel,Zara Patel,Maria Peris Celda,Carlos D. Pinheiro‐Neto,Carl Snyderman,Brian D. Thorp,Jamie J. Van Gompel,Georgios Zenonos,Nathan T. Zwagerman,Olabisi Sanusi,Eric W. Wang,Mathew Geltzeiler
DOI: https://doi.org/10.1002/alr.23351
2024-04-05
International Forum of Allergy & Rhinology
Abstract:Background With modern treatment paradigms, olfactory neuroblastoma (ONB) has favorable overall survival (OS); however, the incidence of recurrence remains high. The primary aims of this study were to delineate the prognosis of recurrence of ONB and explore how recurrence subsites are associated with OS, disease‐specific survival (DSS), and further recurrence. Methods A retrospective chart review of ONB cases from nine academic centers between 2005 and 2021 was completed. Tumor characteristics, recurrence subsites, timelines to recurrence, additional recurrences, and survival estimates were determined using descriptive and time‐to‐event analyses. Results A final cohort of 233 patients was identified, with 70 (30.0%) patients recurring within 50.4 (standard deviation ±40.9) months of diagnosis on average, consisting of local (50%), neck (36%), intracranial (9%), and distant (6%) recurrence. Compared with subjects without recurrence, patients with recurrence had significantly different primary American Joint Committee on Cancer T stage (p
otorhinolaryngology